Why the study?
Does a reduction in heart rate variability (SDNN) predict mortality better than conventional clinical measurements in patients with chronic heart failure?
Does a reduction in heart rate variability (SDNN) predict mortality better than conventional clinical measurements in patients with chronic heart failure?
Reduced heart rate variability (SDNN) is a strong predictor of mortality in chronic heart failure, identifying high-risk patients who may need additional therapy beyond ACE inhibitors.
CHF is associated with autonomic dysfunction, which can be quantified by measuring HRV. A reduction in SDNN identifies patients at high risk of death and is a better predictor of death due to progressive heart failure than other conventional clinical measurements. High-risk subgroups identified by this measurement are candidates for additional therapy after prescription of an ACE inhibitor.
No takes yet. Share an insight, caveat, or question.
Nolan et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: